Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 386 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma MOST POPULAR Woman Suffers Seizure And Dies After Making Fatal Error With Her... May 3, 2019 New Drugs, New Side Effects: Complications of Cancer Immunotherapy May 10, 2019 EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... November 8, 2021 Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched... May 26, 2023 Load more HOT NEWS NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide... Having Cancer as a Young Adult Put Me on a Path... Sleep Issue Called Hypersomnolence Can Increase The Risk Of Diabetes And...
